Nitric oxide (NO) signaling as a potential therapeutic modality against psychostimulants.

Shervin Liddie, Mara A. Balda, Yossef Itzhak

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.

Original languageEnglish
Pages (from-to)7092-7102
Number of pages11
JournalCurrent Pharmaceutical Design
Volume19
Issue number40
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Methamphetamine
Nitric Oxide
Addictive Behavior
Cocaine
Social Problems
Therapeutics
Reward
Free Radicals
Maintenance
Phenotype
Drug Therapy
Health

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Nitric oxide (NO) signaling as a potential therapeutic modality against psychostimulants. / Liddie, Shervin; Balda, Mara A.; Itzhak, Yossef.

In: Current Pharmaceutical Design, Vol. 19, No. 40, 01.12.2013, p. 7092-7102.

Research output: Contribution to journalArticle

Liddie, Shervin ; Balda, Mara A. ; Itzhak, Yossef. / Nitric oxide (NO) signaling as a potential therapeutic modality against psychostimulants. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 40. pp. 7092-7102.
@article{ea0619c9efb34cfc82dd94c7896672a7,
title = "Nitric oxide (NO) signaling as a potential therapeutic modality against psychostimulants.",
abstract = "Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.",
author = "Shervin Liddie and Balda, {Mara A.} and Yossef Itzhak",
year = "2013",
month = "12",
day = "1",
language = "English",
volume = "19",
pages = "7092--7102",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "40",

}

TY - JOUR

T1 - Nitric oxide (NO) signaling as a potential therapeutic modality against psychostimulants.

AU - Liddie, Shervin

AU - Balda, Mara A.

AU - Itzhak, Yossef

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.

AB - Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.

UR - http://www.scopus.com/inward/record.url?scp=84906795690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906795690&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 7092

EP - 7102

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 40

ER -